4.9.5.4Vertical
Toxicology & Drug Testing Labs
Labs performing urine, blood, and oral fluid drug testing.
Market snapshot
These figures describe Laboratory & Diagnostic Services (4.9.5), the segment that Toxicology & Drug Testing Labs sits within — not Toxicology & Drug Testing Labs on its own.
- Market size
- ~$76B
- Growth
- ~10.1%CAGR (2017–22, nominal)
- Companies
- ~14,900
FragmentationConsolidatingEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 621511 (Medical Laboratories) + 621991 (Blood & Organ Banks); 2022 figures are inflated by the COVID-testing surge.
Business model & economics
Revenue model
Per-test reimbursement across clinical and specialty testing
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 15–25%
- Capex intensity
- High
recurring testing volume
Characteristics
- Reference-lab market consolidated around Labcorp and Quest.
- COVID-testing surge inflated 2020–22, then normalized.
- Molecular and genetic testing the durable growth driver.
M&A deal context
Deal activityHigh
Who’s acquiring
- Reference-lab majors
- Genomic & specialty-testing acquirers
- PE-backed lab consolidators
What’s driving deals
- Acquisition of hospital outreach and specialty labs.
- Molecular and precision-diagnostics growth.
- Consolidation around scaled reference labs.
Find Toxicology & Drug Testing Labs acquisition targets
Search Acquisera’s index for companies classified under Toxicology & Drug Testing Labs (4.9.5.4) and build a targeted deal pipeline.
Search companies